AU2001287043A1 - Modulators of us28 (chemokines) for treating cytomegalovirus infections - Google Patents

Modulators of us28 (chemokines) for treating cytomegalovirus infections

Info

Publication number
AU2001287043A1
AU2001287043A1 AU2001287043A AU8704301A AU2001287043A1 AU 2001287043 A1 AU2001287043 A1 AU 2001287043A1 AU 2001287043 A AU2001287043 A AU 2001287043A AU 8704301 A AU8704301 A AU 8704301A AU 2001287043 A1 AU2001287043 A1 AU 2001287043A1
Authority
AU
Australia
Prior art keywords
chemokines
modulators
cytomegalovirus infections
treating cytomegalovirus
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287043A
Inventor
Daniel J. Dairaghi
Brian E. Mcmaster
Thomas J. Schall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2001287043A1 publication Critical patent/AU2001287043A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001287043A 2000-08-30 2001-08-30 Modulators of us28 (chemokines) for treating cytomegalovirus infections Abandoned AU2001287043A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22897400P 2000-08-30 2000-08-30
US60/228,974 2000-08-30
PCT/US2001/027363 WO2002017900A2 (en) 2000-08-30 2001-08-30 Modulators of us28 (chemokines) for treating cytomegalovirus infections

Publications (1)

Publication Number Publication Date
AU2001287043A1 true AU2001287043A1 (en) 2002-03-13

Family

ID=22859306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287043A Abandoned AU2001287043A1 (en) 2000-08-30 2001-08-30 Modulators of us28 (chemokines) for treating cytomegalovirus infections

Country Status (2)

Country Link
AU (1) AU2001287043A1 (en)
WO (1) WO2002017900A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017969A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Reagents and methods for the diagnosis of cmv dissemination
AU2001288682A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US6821998B2 (en) 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
EP1393728A1 (en) * 2002-08-30 2004-03-03 Vrije Universiteit Inverse agonists acting at virus-encoded G protein-coupled receptors
EP2462952A1 (en) 2010-12-10 2012-06-13 Medizinische Universität Graz Cancer gene therapy using nucleic acids encoding US28

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI46164B (en) * 1965-06-22 1972-10-02 Spofa Vereinigte Pharma Werke
AU771946B2 (en) * 1998-08-31 2004-04-08 Oregon Health And Science University Prevention of cell migration initiation with CMV US28 receptor antagonists
WO2002017969A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Reagents and methods for the diagnosis of cmv dissemination
AU2001288682A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination

Also Published As

Publication number Publication date
WO2002017900A2 (en) 2002-03-07
WO2002017900A9 (en) 2002-06-06
WO2002017900A3 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
AU2001255727A1 (en) Component architecture for medical device system networks
AU2002229897A1 (en) Repetition coding for optical networks of computing devices
AU2001274907A1 (en) Menses specific absorbent systems
AU7570400A (en) Micromachined optomechanical switching devices
AU1936401A (en) Photodefinition of optical devices
AU2002320116A1 (en) Modular computing system
HUP0302630A3 (en) Sterilisation of pharmaceuticals
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2002324718A1 (en) Catamenial device
AUPR113300A0 (en) Pour-on application method and devices
AU2001271355A1 (en) Single-channel attenuators
AU2281601A (en) Treatment of viral infections using levovirinTM
AU2001287043A1 (en) Modulators of us28 (chemokines) for treating cytomegalovirus infections
AU2001280013A1 (en) Optical devices
AU2002359327A1 (en) Method of treating viral infections
AU2002224137A1 (en) Coating device
AU2001282473A1 (en) Mode coupled optomechanical devices
AU2001258675A1 (en) Treating infections
AU3098099A (en) Biological modification of vaso-occlusive devices
AU2001288870A1 (en) Antiviral compounds and method of treating viral infections
AU2002224845A1 (en) Viral expression system
AU2002366168A1 (en) Rights expression system
AU3188400A (en) Passive range determination of object
AU2001264856A1 (en) Inhibitors of viral infection
AU4706799A (en) Treatment of (staphylococcus) infections